Apellis Pharmaceuticals (APLS)

Executive Summary

Apellis Pharmaceuticals is a global biopharmaceutical company specializing in targeted C3 therapies for complement-driven diseases. Its approved products, EMPAVELI (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH) and SYFOVRE (pegcetacoplan) for geographic atrophy (GA) secondary to age-related macular degeneration, have established a commercial foothold. The pipeline includes late-stage trials in C3 glomerulopathy (C3G) and IgA nephropathy, as well as earlier programs in delayed graft function and combination therapies for GA. Despite competitive pressure in GA from rivals like Iveric Bio and Roche, Apellis's C3 targeting offers differentiation. Key near-term focus will be on commercialization execution, expansion into new geographies, and data readouts from ongoing Phase 3 trials that could support label expansions or new indications.

Upcoming Catalysts (preview)

• H2 2026Phase 3 VALIANT trial data readout for pegcetacoplan in C3G70% success
• Q2 2026Regulatory decision in EU for SYFOVRE in geographic atrophy60% success
• Q2 2026Earnings release with updated SYFOVRE sales guidance90% success